Drugs / Tolimidone
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT03279263 | Sep 2017 → Sep 2019 | type 2 diabetes mellitus | Melior Pharmaceuticals | Unknown | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02317796 Comparator | Dec 2014 → Dec 2015 | type 2 diabetes mellitus | Melior Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2016-12-19 | Bukwang Pharmaceutical | Regulatory 부광약품, 당뇨병 신약 MLR-1023 후기 2상 임상시험 신청 bukwang.co.kr ↗
부광약품은 최근 식품의약품안전처에 제2형 당뇨병 치료제 후보물질인 ‘MLR-1023’의 후기 2상 임상시험계획에 대한 승인신청을 제출하였다고 밝혔다. |
All press releases naming this drug 12 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tolimidone | “AIM: MLR-1023, called Tolimidone when evaluated unsuccessfully by Pfizer for gastric ulcer disease, has been repurposed as a novel oral insulin sensitizer with its effects...” PMID 32019723 ↗ Feb 2020 |
| Known as | CP-26,154 | ChEMBL registry synonym — accepted as the source's own label CHEMBL8030 ↗ |
| Known as | MLR-1023 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02317796 ↗ |
| Known as | NSC-314335 | ChEMBL registry synonym — accepted as the source's own label CHEMBL8030 ↗ |
| Known as | Tolimidona | ChEMBL registry synonym — accepted as the source's own label CHEMBL8030 ↗ |
| Action | Activate | “selective activation of Lyn kinase” PMID 32019723 ↗ Feb 2020 |
| Modality | Small molecule | — CHEMBL8030 ↗ |
| Route | Oral | “Each subject will receive an oral dose of placebo or MLR-1023 once before breakfast” NCT02317796 ↗ |
| Target | LYN | “selective activation of Lyn kinase” PMID 32019723 ↗ Feb 2020 |